Synonym |
Thai / English name |
Part Used : ใบActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 14*N(Treatment) : 7**Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : Voriconazole 200 mg after administration of Ginkgo biloba 120 mg twice daily.Duration : 12 daysType of interaction : PharmacokineticsInteraction with drug : VoriconazoleDose/Conc.(drug) : -Result : EquivocalRemark : * Healthy and nonsmoking volunteers. ** CYP2C19 extensive metabolizers (2C19*1/2C19*1). Results: For extensive metabolizers, the median value for voriconazole area under the plasma concentration time cruve from zero to infinity (AUC0-infinity) was 5.17 microgram/mL after administration of voriconazole alone and 4.28 microgram/mL after voriconazole with Ginkgo biloba (p>0.05). The other pharmacokinetic parameters of voriconazole such as AUC0-24, time to reach maximum concentration, half-life, and apparent clearance also did not change significantly for expensive metabolizers in the presence of Ginkgo biloba.Note : - 2 phase randomized crossover study with 4 weeks washout between phases. - Data incomplete.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 14*N(Treatment) : 7**Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : Voriconazole 200 mg after administration of Ginkgo biloba 120 mg twice daily.Duration : 12 daysType of interaction : PharmacokineticsInteraction with drug : VoriconazoleDose/Conc.(drug) : -Result : EquivocalRemark : * Healthy and nonsmoking volunteers. ** CYP2C19 extensive metabolizers (2C19*1/2C19*1). Results: For extensive metabolizers, the median value for voriconazole area under the plasma concentration time cruve from zero to infinity (AUC0-infinity) was 5.17 microgram/mL after administration of voriconazole alone and 4.28 microgram/mL after voriconazole with Ginkgo biloba (p>0.05). The other pharmacokinetic parameters of voriconazole such as AUC0-24, time to reach maximum concentration, half-life, and apparent clearance also did not change significantly for expensive metabolizers in the presence of Ginkgo biloba.Note : - 2 phase randomized crossover study with 4 weeks washout between phases. - Data incomplete.
Part Used : ใบActivity : CYP2C19 INDUCTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 14*N(Treatment) : 7**Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : Voriconazole 200 mg after administration of Ginkgo biloba 120 mg twice daily.Duration : 12 daysType of interaction : PharmacokineticsInteraction with drug : VoriconazoleDose/Conc.(drug) : -Result : EquivocalRemark : * Healthy and nonsmoking volunteers. ** CYP2C19 extensive metabolizers (2C19*1/2C19*1). Results: For extensive metabolizers, the median value for voriconazole area under the plasma concentration time cruve from zero to infinity (AUC0-infinity) was 5.17 microgram/mL after administration of voriconazole alone and 4.28 microgram/mL after voriconazole with Ginkgo biloba (p>0.05). The other pharmacokinetic parameters of voriconazole such as AUC0-24, time to reach maximum concentration, half-life, and apparent clearance also did not change significantly for expensive metabolizers in the presence of Ginkgo biloba.Note : - 2 phase randomized crossover study with 4 weeks washout between phases. - Data incomplete.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 14*N(Treatment) : 7**Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : Voriconazole 200 mg after administration of Ginkgo biloba 120 mg twice daily.Duration : 12 daysType of interaction : PharmacokineticsInteraction with drug : VoriconazoleDose/Conc.(drug) : -Result : EquivocalRemark : * Healthy and nonsmoking volunteers. ** CYP2C19 poor metabolizers (2C19*2/2C19*2). Results: Pharmacokinetic parameters of voriconazole for poor metabolizers were similar pattern of extensive metabolizers.Note : - 2 phase randomized crossover study with 4 weeks washout between phases. - Data incomplete.
Part Used : ใบActivity : CYP2C19 INDUCTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 14*N(Treatment) : 7**Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : Voriconazole 200 mg after administration of Ginkgo biloba 120 mg twice daily.Duration : 12 daysType of interaction : PharmacokineticsInteraction with drug : VoriconazoleDose/Conc.(drug) : -Result : EquivocalRemark : * Healthy and nonsmoking volunteers. ** CYP2C19 poor metabolizers (2C19*2/2C19*2). Results: Pharmacokinetic parameters of voriconazole for poor metabolizers were similar pattern of extensive metabolizers.Note : - 2 phase randomized crossover study with 4 weeks washout between phases. - Data incomplete.
Part Used : ใบActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 14*N(Treatment) : 7**Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : Voriconazole 200 mg after administration of Ginkgo biloba 120 mg twice daily.Duration : 12 daysType of interaction : PharmacokineticsInteraction with drug : VoriconazoleDose/Conc.(drug) : -Result : EquivocalRemark : * Healthy and nonsmoking volunteers. ** CYP2C19 poor metabolizers (2C19*2/2C19*2). Results: Pharmacokinetic parameters of voriconazole for poor metabolizers were similar pattern of extensive metabolizers.Note : - 2 phase randomized crossover study with 4 weeks washout between phases. - Data incomplete.